Vidal M Arroyo1, Philip J Lupo2, Michael E Scheurer2, Surya P Rednam2, Jeffrey Murray3, M Fatih Okcu2, Murali M Chintagumpala2, Austin L Brown4. 1. Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA. 2. Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA; Texas Children's Cancer and Hematology Centers, Houston, TX, USA. 3. Cook Children's Medical Center, Ft. Worth, TX, USA. 4. Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA; Texas Children's Cancer and Hematology Centers, Houston, TX, USA. Electronic address: Austin.Brown@bcm.edu.
Abstract
INTRODUCTION: Methylation-derived neutrophil-to-lymphocyte ratio (mdNLR) has been identified as a potential prognostic biomarker of outcomes in various cancers. We evaluated the prognostic value of blood-derived mdNLR within a retrospective cohort of pediatric medulloblastoma patients. MATERIALS AND METHODS: DNA methylation was measured in archival peripheral blood samples collected on 56 pediatric medulloblastoma patients. Hazard ratios (HR) and 95% confidence intervals (CI) for the association between mdNLR and survival were evaluated using Cox proportional hazard models. RESULTS: Compared to patients who were alive at last follow-up (n = 43), the mean mdNLR value was slightly higher in deceased patients (n = 13) (12.3 vs. 5.2,P = 0.163). Elevated log-transformed mdNLR was suggestively associated with an increased likelihood of death in unadjusted models (HR=1.43, 95%CI: 0.92-2.22) and significantly associated with mortality in adjusted models (HR=1.61, 95%CI: 1.01-2.58). DISCUSSION: Future work is warranted to investigate the relationship between mdNLR outcomes in specific pediatric medulloblastoma molecular subgroups.
INTRODUCTION: Methylation-derived neutrophil-to-lymphocyte ratio (mdNLR) has been identified as a potential prognostic biomarker of outcomes in various cancers. We evaluated the prognostic value of blood-derived mdNLR within a retrospective cohort of pediatric medulloblastomapatients. MATERIALS AND METHODS: DNA methylation was measured in archival peripheral blood samples collected on 56 pediatric medulloblastomapatients. Hazard ratios (HR) and 95% confidence intervals (CI) for the association between mdNLR and survival were evaluated using Cox proportional hazard models. RESULTS: Compared to patients who were alive at last follow-up (n = 43), the mean mdNLR value was slightly higher in deceased patients (n = 13) (12.3 vs. 5.2,P = 0.163). Elevated log-transformed mdNLR was suggestively associated with an increased likelihood of death in unadjusted models (HR=1.43, 95%CI: 0.92-2.22) and significantly associated with mortality in adjusted models (HR=1.61, 95%CI: 1.01-2.58). DISCUSSION: Future work is warranted to investigate the relationship between mdNLR outcomes in specific pediatric medulloblastoma molecular subgroups.
Authors: Christina D Pham; Catherine Flores; Changlin Yang; Elaine M Pinheiro; Jennifer H Yearley; Elias J Sayour; Yanxin Pei; Colin Moore; Roger E McLendon; Jianping Huang; John H Sampson; Robert Wechsler-Reya; Duane A Mitchell Journal: Clin Cancer Res Date: 2015-09-24 Impact factor: 12.531
Authors: Graeme J K Guthrie; Kellie A Charles; Campbell S D Roxburgh; Paul G Horgan; Donald C McMillan; Stephen J Clarke Journal: Crit Rev Oncol Hematol Date: 2013-04-17 Impact factor: 6.312
Authors: Devin C Koestler; Joseph Usset; Brock C Christensen; Carmen J Marsit; Margaret R Karagas; Karl T Kelsey; John K Wiencke Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-13 Impact factor: 4.254
Authors: Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister Journal: Acta Neuropathol Date: 2011-12-02 Impact factor: 17.088